The company has received 580k EUR in funding from the EU’s EUROSTARS program.
Pilloxa is developing digital patient-centric solutions and will, together with the University of Oslo, now validate an innovation that supports the patient to take their medication as prescribed and further develop the solution to increase the quality and effectiveness of drug treatment in both the healthcare setting and during clinical trials.
“There has never been a greater need for supporting patients in their journey and improving the efficiency of clinical trials.”
“Pilloxa would like to thank the European Commission and the intergovernmental innovation network EUREKA for selecting Pilloxa to receive funding and for supporting our mission of working towards optimizing clinical trials through technology. There has never been a greater need for supporting patients in their journey and improving the efficiency of clinical trials. Pilloxa’s focus on patients’ needs coupled with our user friendly technology can make a great impact. This funding will help us clinically validate our technological solutions in a large patient population while further developing our integration with Health Care Providers and trials,” says Francesco Mazzotta, CEO of Pilloxa.
The ASTORIA study
The ASTORIA study will show the effect of Pilloxa’s solution upon adherence to the medicine Rivaroxaban. The study is the first of its kind in the field and the hope is that the results will lay the foundation for the next step in patient-centered drug development and treatment.
The funds will also be used for further development of a complete digital system that facilitates the process both for the patients included in the study and for the investigator. In addition, the reliability of the collected data will be strengthened, which can both reduce costs and be considered more ethical. Bayer and Pilloxa are already partners and Bayer is also a financial sponsor of the ASTORIA project.
The ASTORIA study is meant to validate the solution in a real world clinical setting with the goal of providing statistical significant evidence that Pilloxa’s solution can improve persistence to medication in newly diagnosed patients with atrial fibrillation, it states. The clinical study will be multicenter and use the full suite of Pilloxa services to enable remote patient monitoring. The data and input acquired during the trial will be used to further develop Pilloxa’s solution and expand its commercial reach. The funding will be split between Pilloxa and the University of Oslo, with the majority going to Pilloxa.
The project is expected to begin in Autumn of this year and will continue until 2022.